KDR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is employed for Philadelphia chromosome‐positive chronic granulocytic leukemia treatment, sorafenib has shown efficacy in advanced renal cell carcinoma treatment, and ongoing trials involve tivozanib targeting VEGFR for related diseases.28